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Interleukin-2 receptor monoclonal antibodies in renal
transplantation: meta-analysis of randomised trials
Dwomoa Adu, Paul Cockwell, Natalie J Ives, Jonathan Shaw, Keith Wheatley
Abstract
Objective To study the effect of interleukin-2 receptor
monoclonal antibodies on acute rejection episodes,
graft loss, deaths, and rate of infection and
malignancy in patients with renal transplants.
Design Meta-analysis of published data.
Data sources Medline, Embase, and Cochrane library
for years 1996-2003 plus search of medical editors’
trial amnesty and contact with manufacturers of the
antibodies.
Selection of studies Randomised controlled trials
comparing interleukin-2 receptor antibodies with
placebo or no additional treatment in patients with
renal transplants receiving ciclosporin based
immunosuppression.
Results Eight randomised controlled trials involving
1871 patients met the selection criteria (although only
1858 patients were analysed). Interleukin-2 receptor
antibodies significantly reduced the risk of acute
rejection (odds ratio 0.51, 95% confidence interval
0.42 to 0.63). There were no significant differences in
the rate of graft loss (0.78, 0.58 to 1.04), mortality
(0.75, 0.46 to 1.23), overall incidence of infections
(0.97, 0.77 to 1.24), incidence of cytomegalovirus
infections (0.81, 0.62 to 1.04), or risk of malignancies
at one year (0.82, 0.39 to 1.70). The different
antibodies had a similar sized effect on acute rejection
(test for heterogeneity P=0.7): anti-Tac (0.37, 0.16 to
0.89), BT563 (0.37, 0.1 to 1.38), basiliximab (0.56, 0.44
to 0.72), and daclizumab (0.46, 0.32 to 0.67). The
reduction in acute rejections was similar for all
ciclosporin based immunosuppression regimens (test
for heterogeneity P=1.0).
Conclusions Adding interleukin-2 receptor
antibodies to ciclosporin based immunosuppression
reduces episodes of acute rejection at six months by
49%. There is no evidence of an increased risk of
infective complications. Longer follow up studies are
needed to confirm whether interleukin-2 receptor
antibodies improve long term graft and patient
survival.
Introduction
Over 15 000 people in the United Kingdom have func-
tioning renal transplants, almost half of all patients
with end stage renal failure.1 Episodes of acute
rejection reduce the chance of long term survival of
the graft.2 3 However, increasing immunosuppression
to lower the risk of acute rejection or to treat episodes
of acute rejection increases the incidence of infections
and malignancies.4 5
Acute rejection arises when alloreactive T cells
infiltrate the graft. A critical step in the activation of
these cells is the expression of the high affinity
interleukin-2 receptor, which induces rapid prolifera-
tion of T cells when interleukin-2 binds to it.6 The
interleukin-2 receptor consists of three transmem-
brane protein chains:  (CD25),  (CD122), and 
(CD132). CD25 does not transduce a signal but associ-
ates with CD122 and CD132 to form the receptor that
triggers signalling.7
Initial human studies with mouse monoclonal anti-
bodies to CD25 showed a significant reduction in acute
rejection, but patients developed anti-mouse antibod-
ies.8 9 Chimeric and humanised antibodies to CD25
have been developed to overcome the problem of
immunogenicity, but individual trials are not large
enough to be clear about the effectiveness of these
antibodies. We did a systematic review and quantitative
meta-analysis of randomised trials of interleukin-2
receptor antibodies versus placebo in patients receiv-
ing ciclosporin based immunosuppression after renal
transplantation.
Methods
Literature search
We searched Medline for studies published between
1966 and 2003 with the following search terms:
basiliximab, daclizumab, Simulect, Zenapax, anti-Tac,
LO-TACT-1, antibodies, monoclonal, receptors,
interleukin-2, randomised controlled trial, clinical trial,
double-blind, renal, and kidney transplantation. We
used a similar search strategy in the Embase and
Cochrane Library databases. To locate unpublished
studies, we searched the medical editors’ trial amnesty
and contacted Novartis and Roche, the manufacturers
of basiliximab and daclizumab. We also searched the
reference lists of identified papers and previous
reviews for relevant studies.
Selection of trials
Studies had to meet the following criteria: treatment
assigned by randomisation; all patients received stand-
ard immunosuppression; the experimental group
received interleukin-2 receptor antibody; the control
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group received placebo or no other drug. Three inves-
tigators (JS, DA, and NJI) examined each eligible study
and recorded method of randomisation, treatment in
both arms of the study, and outcome measures. They
also recorded details of actual treatment and its
duration.
Outcome measures and statistics
The main outcomemeasures were biopsy proved acute
rejection at six months after transplantation, graft loss
and death at 12 months, and incidence of infections,
cytomegalovirus infections, and malignancy at 3, 6, or
12 months.
One study excluded data on 20 control patients
and 19 patients treated with basiliximab from the
analysis of acute rejection because biopsy samples were
not taken according to the protocol.10 Four studies
excluded data from a total of 11 patients who did not
receive a transplant10–12 or lost their grafts because of
technical reasons or renal artery thrombosis.9
We determined the number of patients with each
outcome measure in the antibody and control groups
for each trial from the published papers. We then used
standard methods for overviews based on published
data.13 To summarise, for each trial we calculated the
expected number of events in the interleukin-2 group
and then the difference between the observed and
expected numbers and its variance. The sum of the sta-
tistics for each trial provided the overall statistics, which
we used to calculate odd ratios with 95% confidence
intervals. All P values are two tailed.
Results
Eight trials fulfilled the inclusion criteria.8–12 14–16 The
table summarises the baseline characteristics of
patients in these studies. Four studies used cadaveric
donors only,8 10 11 14 and four studies included both
cadaveric and living donors.9 12 15 16 Two of the studies
included patients receiving second transplants.15 16 All
but one of the studies8 used a double blind method of
randomisation. Four studies described the method of
randomisation in detail, of which one used sealed
envelopes,8 two used 1:1 randomisation,12 16 and one
assigned randomly in a 1:1 ratio using an automated
randomisation program at each centre and held the
results in a set of sealed envelopes.10 In one study, the
patients in the control arm did not receive placebo.8
The baseline immunosuppression varied between
studies. Four studies used ciclosporin and
prednisolone,9–12 three studies used ciclosporin, aza-
thioprine, and prednisolone,8 14 16 and one study used
ciclosporin, mycophenolate mofetil, and pred-
nisolone.15 Two studies gave both ciclosporin dose and
target concentrations,9 16 two studies defined target
ciclosporin concentrations,10 11 and three studies gave
the dose of ciclosporin.8 11 15 All but one study, which
used ciclosporin, azathioprine, and steroids,14 gave
doses of the other immunosuppressants used.
The overall proportion of patients with acute rejec-
tion at six months was 361/912 (39.6%) in the control
group compared with 232/904 (25.7%) in the antibody
group (fig 1). Treatment with interleukin-2 receptor
antibodies was associated with a significant reduction
in the risk of acute rejection at six months (odds ratio
0.51; 95% confidence interval 0.42 to 0.63; P < 0.0001).
Figures 2 and 3 show that patients treated with
antibodies had no significant reductions in graft loss at
one year (0.78, 0.58 to 1.04; P=0.09) or in mortality at
one year (0.75, 0.46 to 1.23; P=0.3).
Anti-Tac
Kirkman 19918
BT563
van Gelder 19959
Basiliximab
Nashan 1997*10
Kahan 199912
Lawen 200015
Ponticelli 200116
Subtotal
Test for heterogeneity between trials: χ2=0.1, P=1.0
Daclizumab
Vincenti 199814
Nashan 199911
Subtotal
Test for heterogeneity between trials: χ2=0.1, df=1, P=0.7
Total
Test for heterogeneity (8 trials): χ2=1.8, df=7, P=1.0
Test for heterogeneity between subtotals: χ2=1.5, df=3, P=0.7
* One centre was excluded from this analysis because biopsy samples were not taken according to protocol
14/40
3/27
51/171
57/173
9/59
31/168
148/571
28/126
39/140
67/266
232/904
(25.9%)
(25.2%)
(25.7%)
24/40
8/30
73/166
79/173
17/64
50/172
219/575
47/134
63/133
110/267
361/912
-5.0
-2.2
-11.9
-11.0
-3.5
-9.0
-35.4
-8.8
-13.3
-22.1
-64.7
5.1
2.2
19.6
20.7
5.2
15.5
61.0
12.7
16.0
28.7
97.0
0.37 (0.16 to 0.89)
0.37 (0.10 to 1.38)
0.54 (0.35 to 0.85)
0.59 (0.38 to 0.90)
0.51 (0.22 to 1.21)
0.56 (0.34 to 0.92)
0.56 (0.44 to 0.72)
0.50 (0.29 to 0.87)
0.44 (0.27 to 0.71)
0.46 (0.32 to 0.67)
0.51 (0.42 to 0.63)
(38.1%)
(41.2%)
0.1 1.0 10.0
Antibody better Control better
(39.6%)
P<0.0001
P<0.0001
Effect P<0.0001
Trial Antibody Variance Odds ratio
(95% CI)
Odds ratio
(95% CI)
Observed
-expected
Control
No of rejections/
No of patients
Fig 1 Incidence of acute rejection by type of interleukin-2 receptor antibody. Note that only
overall follow up data (six to 26 months) were available for anti-Tac and 12 week data for
BT563
Anti-Tac
Kirkman 19918
BT563
van Gelder 19959
Basiliximab
Nashan 199710
Kahan 199912
Lawen 200015
Ponticelli 200116
Daclizumab
Vincenti 199814
Nashan 199911
Total
Test for heterogeneity (8 trials): χ2=2.6, df=7, P=0.9
Test for heterogeneity between subtotals: χ2=2.1, df=3, P=0.6
7/40
9/30
23/190
9/173
3/59
16/168
6/126
16/140
89/926
(9.6%) (11.9%)
6/40
8/30
25/186
12/173
5/64
20/172
13/134
22/133
111/932
0.5
0.5
-1.3
-1.5
-0.8
-1.8
-3.2
-3.5
-11.1
2.8
3.1
10.5
5.0
1.9
8.1
4.4
8.2
43.9
1.20 (0.37 to 3.90)
1.18 (0.39 to 3.58)
0.89 (0.48 to 1.62)
0.74 (0.31 to 1.78)
0.64 (0.15 to 2.68)
0.80 (0.40 to 1.60)
0.48 (0.19 to 1.23)
0.65 (0.33 to 1.30)
0.78 (0.58 to 1.04)
0.1 1.0 10.0
Antibody better Control better
Effect P=0.09
Trial Antibody Variance Odds ratio
(95% CI)
Odds ratio
(95% CI)
Observed
-expected
Control
No of graft loss/
No of patients
Fig 2 Incidence of graft loss at one year by type of interleukin-2 receptor antibody
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The proportion of patients with infections and
cytomegalovirus infection was reported at three
months in one trial,9 at six months in four trials,11 14–16
and at 12 months in three trials.8 10 12 However in three
trials the data were not given in a form that was evalu-
able.8 9 14 Treatment with interleukin-2 receptor anti-
bodies had no significant effect on overall infection
(0.97, 0.77 to 1.24; P=0.8; fig 4) or cytomegalovirus
infection (0.81, 0.62 to 1.04; P=0.1; fig 5). Fig 6 shows
there was no difference in the risk of lymphoma or
other malignancies at one year (0.82, 0.39 to 1.70;
P=0.6).
The effect on acute rejection was similar for all
types of interleukin-2 receptor antibody (fig 1): anti-Tac
(0.37, 0.16 to 0.89; P=0.03), BT563 (0.37, 0.1 to 1.38;
P=0.1), basiliximab (0.56, 0.44 to 0.72; P < 0.0001), and
daclizumab (0.46, 0.32 to 0.67; P < 0.0001). The test for
heterogeneity between antibody groups was not
significant (P=0.7).
The reduction in acute rejection was similar for all
baseline immunosuppression regimens (fig 7). The
odds ratio was 0.52 (95% confidence interval 0.40 to
0.67; P < 0.0001) for patients treated with ciclosporin
and prednisolone; 0.5 (0.36 to 0.71; P < 0.0001) with
ciclosporin, prednisolone, and azathioprine; and 0.51
(0.22 to 1.21; P=0.1) with ciclosporin, prednisolone,
and mycophenolate mofetil. There was no evidence of
heterogeneity between the three immunosuppression
treatment groups (P=1.0) or between the trials for any
of the other outcomes.
Discussion
This meta-analysis confirms that adding interleukin-2
receptor antibodies to standard ciclosporin based
immunosuppression greatly reduces the risk of
rejection. Acute rejection proved by biopsy was
reduced by 49% at six months. We also found
non-significant reductions in graft loss and mortality,
and there was no evidence of increased incidence of
infections or risk of malignancy. The size of the reduc-
tion in acute rejections was similar for the different
antibodies and immunosuppression regimens.
Reducing the rate of acute rejection is important in
renal transplantation, as patients who have had one or
more episodes of acute rejection have at least a 50%
reduction in long term graft survival.2 Because one
Monoclonal antibody and baseline characteristics of patients in studies included in analysis. Patient values are for interleukin receptor
antibody group/control group (placebo or no additional treatment)
Characteristic Kirkman 19918
van Gelder
19959
Nashan
199710
Vincenti
199814 Nashan 199911 Kahan 199912 Lawen 200315
Ponticelli
200116
Monoclonal antibody MurineIgG2a MurineIgG1 Basiliximab Daclizumab Daclizumab Basiliximab Basiliximab Basiliximab
No of patients 40/40 30/30 193/187 126/134 140/133 173/173 59/64 168/172
Mean age (years) 44/44 43/45* 49/48* 47/47 44/46 45/46 45/46 44/44
% men 58/65 60/63 66/63 59/60 74/67 64/62 76/64 66/69
% having first transplant 100/100 100/100 100/100 100/100 100/100 100/100 90/88 93/94
Diagnosis (%):
Glomerulonephritis 45/35 NA 32/40 26/30 43/41 NA 30/29 NA
Hereditary 28/25 NA 17/17 19/15 15/14 NA 10/15 NA
Pyelonephritis/
interstitial nephritis
NA† NA 10/10 NA 13/11 NA 10/6 NA
Diabetes 0/5 NA 7/5 25/22 3/8 NA 10/6 NA
Other or unknown 25/30 NA 35/28 29/33 26/26 NA 40/43 NA
NA=not available.
*Ages given as median.
†Pyelonephritis numbers not stated. One patient in each group had interstitial nephritis.
Anti-Tac
Kirkman 19918
BT563
van Gelder 19959
Basiliximab
Nashan 199710
Kahan 199912
Lawen 200015
Ponticelli 200116
Daclizumab
Vincenti 199814
Nashan 199911
Total
Test for heterogeneity (7 trials): χ2=10.3, df=6, P=0.1
Test for heterogeneity between subtotals: χ2=7.3, df=3, P=0.06
5/40
2/30
9/190
5/173
0/59
4/168
3/126
1/140
29/926
(3.1%) (4.1%)
2/40
6/30
5/186
7/173
0/64
5/172
5/134
8/133
38/932
1.5
-2.0
1.9
-1.0
-0.4
-0.9
-3.6
-4.5
1.6
1.8
3.4
2.9
2.2
1.9
2.2
16.0
2.52 (0.54 to 11.77)
0.32 (0.07 to 1.41)
1.77 (0.61 to 5.14)
0.71 (0.22 to 2.24)
0.82 (0.22 to 3.06)
0.64 (0.16 to 2.60)
0.19 (0.05 to 0.72)
0.75 (0.46 to 1.23)
0.1 1.0 10.0
Antibody better Control better
Effect P=0.3
Trial Antibody Variance Odds ratio
(95% CI)
Odds ratio
(95% CI)
Observed
-expected
Control
No of deaths/
No of patients
Fig 3 Number of deaths at one year by type of interleukin-2 receptor antibody
161/190
129/173
37/59
110/168
105/140
542/730
(74.2%) (74.6%)
161/186
127/173
45/64
113/172
97/133
543/728
-1.7
1.0
-2.3
-0.2
1.4
-1.8
11.6
16.7
6.9
19.2
13.2
67.6
0.86 (0.49 to 1.53)
1.05 (0.68 to 1.72)
0.71 (0.34 to 1.50)
0.99 (0.63 to 1.55)
1.11 (0.65 to 1.91)
0.97 (0.77 to 1.24)
0.1 1.0 10.0
Antibody better Control better
Effect P=0.8
Trial Antibody Variance Odds ratio
(95% CI)
Odds ratio
(95% CI)
Observed
-expected
Control
No of infections/
No of patients
Basiliximab
Nashan 199710
Kahan 199912
Lawen 200015
Ponticelli 200116
Daclizumab
Nashan 199911
Total
Test for heterogeneity (5 trials): χ2=1.2, df=4, P=0.9
Test for heterogeneity between subtotals: χ2=0.3, df=1, P=0.6
Fig 4 Incidence of infection by type of interleukin-2 receptor antibody for studies with
available data
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year graft survival for renal transplantation is about
90%,2 studies with follow up for more than one year are
needed to determine the long term effect on graft loss.
A major concern with the addition of immunosup-
pression to standard regimens is the increased
incidence of side effects. Although we found no
increase in the incidence of malignancies in patients
treated with interleukin-2 receptor antibodies com-
pared with the control group at one year, the follow up
was too short to draw useful conclusions. We found no
evidence of an increase in the risk of infections. This is
important because analyses of treatment with anti-
lymphocyte antibodies in renal allograft recipients
have shown an increased risk of infection.4 5 Finally, we
found some evidence of a reduction in the incidence of
cytomegalovirus infections in patients treated with
antibodies compared with the control group.
Some centres in the United Kingdom use
tacrolimus based immunosuppression. Ameta-analysis
showed that this regimen reduced the risk of acute
rejection but not graft loss compared with ciclosporin
based immunosuppression.17 There are no ran-
domised controlled studies of interleukin-2 receptor
antibodies in patients with renal transplants treated
with tacrolimus based immunosuppression.
Validity of results
Meta-analysis based on published data has some
limitations. The published results were presented as
intention to treat, suggesting that all randomised
patients were included in the analysis. However, one
study excluded data from one centre as it did not
collect biopsy samples according to the protocol.10 Fur-
thermore, three studies defined the intention to treat
analysis as including only patients who actually had
renal transplantation.10–12 Two patients (one patient
from each arm) in two of the studies,11 12 and four
(three from the interleukin-2 group and one from the
placebo group) in the other study10 were therefore
excluded from analysis because they never had a renal
transplant. Another study excluded three patients from
the analysis because they lost their graft because of
technical reasons or renal artery thrombosis.9 These
exclusions mean that the results are not strictly
intention to treat, but the number of patients excluded
is small (11 in total) and therefore unlikely to bias the
results.
As with all meta-analyses of published data, there is
the potential problem of publication bias. We did a
comprehensive literature search to identify published
data and approached the medical editors’ trial
amnesty and antibody manufacturers to try to identify
unpublished studies. It therefore seems unlikely that
this would be a substantial source of bias. Ideally, meta-
analysis should be done on individual patient data, but
this is time consuming and labour intensive.
Conclusions
Our results show that interleukin-2 receptor antibodies
reduce the risk of episodes of acute rejection in
patients with renal transplants. This reduction was not
accompanied by an increased risk of infection. Longer
term studies are now needed to determine the effect
on long term survival of the grafts and the effect on
risk of malignancy.
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Fig 5 Incidence of cytomegalovirus infection by type of interleukin-2 receptor antibody for
studies with available data
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-expected
Control
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No of patients
Fig 6 Incidence of lymphoma and malignancies at one year by type of interleukin-2 receptor
antibody for studies with available data
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Fig 7 Incidence of acute rejection at six months by immunosuppression regimen
What is already known on this topic
Episodes of acute rejection reduce graft survival in
patients with renal transplants
Increasing immunosuppression to reduce
rejection can increase infection and malignancy
What this study adds
Addition of interleukin-2 receptor antibodies to
ciclosporin based immunosuppression regimens
halves the risk of acute rejection
Patients receiving antibodies did not have an
increased risk of infection
The effects on graft loss and mortality at one year
were not significant
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